December 2nd 2024
Risk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.
September 15th 2024
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer
July 31st 2023Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab/chemotherapy as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.
Dostarlimab Has ‘Impactful’ PFS Benefit in dMMR Advanced Endometrial Cancer
June 28th 2023Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Dostarlimab Earns Priority Review From FDA In Advanced Endometrial Cancer
June 6th 2023The FDA accepts a supplemental biologics license application for dostarlimab plus chemotherapy in the treatment of mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer based on data from a prespecified interim analysis of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.
Dostarlimab/Chemo Preserves HRQOL in Advanced/Recurrent Endometrial Cancer
June 4th 2023Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.
Durvalumab Combo Yields Survival Benefit in Advanced Endometrial Cancer
May 29th 2023Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial Cancer
March 27th 2023The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.